ROIV Stock Forecast & Price Target

Roivant Sciences is poised for success due to its diverse portfolio of drug candidates in various stages of development, with positive clinical data and a validated anti-FcRn mechanism. Despite a recent financial update showing lower than expected revenue and higher expenses, the company's strong cash position and successful enrollment in their Phase 2b/3 ALPINE study continue to support their unmet-need thesis. With plans to engage with the FDA in the second half of 2026 and a favorable risk-adjusted revenue estimate, analysts assign a positive outlook for the stock with a Buy rating and a price target of $34.

Roivant Sciences is facing potential approval of Brepocitinib in 3 indications, leading to a major catalyst-heavy second half of 2026. However, with management setting expectations for a measured initial launch and potential concerns over a boxed warning, there may be limited early revenue opportunities. Additionally, with the current off-label use of JAK inhibitors in DM patients only at a low-to-mid single-digit percentage, there may be challenges in gaining significant market share.